An Intermediate Access Protocol for Selumetinib for Treatment of Neurofibromatosis Type 1
Clinical trial NCT03259633 · APPROVED_FOR_MARKETING
Trial details
- NCT number
- NCT03259633
- Sponsor
- AstraZeneca
- Status
- APPROVED_FOR_MARKETING
- Study type
- EXPANDED_ACCESS
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.